{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:45:27Z","timestamp":1789469127793,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Program of the Taizhou School of Clinical Medicine of Nanjing Medical University","award":["TZKY20230106"],"award-info":[{"award-number":["TZKY20230106"]}]},{"name":"Program of the Taizhou School of Clinical Medicine of Nanjing Medical University","award":["TZKY20240201"],"award-info":[{"award-number":["TZKY20240201"]}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20241119"],"award-info":[{"award-number":["BK20241119"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07092-z","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:39:21Z","timestamp":1780479561000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["When AL amyloidosis meets the liver: integrating clinical insight and current understanding"],"prefix":"10.1007","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8061-4955","authenticated-orcid":false,"given":"Yuan","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junling","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruixin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3585-6701","authenticated-orcid":false,"given":"Jianfeng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0122-6995","authenticated-orcid":false,"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"issue":"2","key":"7092_CR1","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/ajh.27177","volume":"99","author":"MA Gertz","year":"2024","unstructured":"Gertz MA (2024) Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment. Am J Hematol 99(2):309\u2013324. https:\/\/doi.org\/10.1002\/ajh.27177","journal-title":"Am J Hematol"},{"issue":"4","key":"7092_CR2","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/ejh.13679","volume":"107","author":"LL Hester","year":"2021","unstructured":"Hester LL, Gifkins DM, Mb K, Vermeulen J, Schecter JM, Strony J et al (2021) Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019. Eur J Haematol 107(4):428\u2013435. https:\/\/doi.org\/10.1111\/ejh.13679","journal-title":"Eur J Haematol"},{"issue":"4","key":"7092_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","volume":"79","author":"MA Gertz","year":"2005","unstructured":"Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN et al (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18\u201322 April 2004. Am J Hematol 79(4):319\u2013328. https:\/\/doi.org\/10.1002\/ajh.20381","journal-title":"Am J Hematol"},{"issue":"3","key":"7092_CR4","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1080\/13506129.2025.2516790","volume":"32","author":"MJ Rees","year":"2025","unstructured":"Rees MJ, Toumeh N, Dispenzieri A, Gertz M, Yohannan B, Atallah-Yunes SA et al (2025) Hepatic involvement in light chain amyloidosis: analysis of 130 patients and predictors of hepatic response and survival. Amyloid 32(3):267\u2013275. https:\/\/doi.org\/10.1080\/13506129.2025.2516790","journal-title":"Amyloid"},{"issue":"7","key":"7092_CR5","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1080\/07853890.2017.1304649","volume":"49","author":"E Muchtar","year":"2017","unstructured":"Muchtar E, Dispenzieri A, Lacy MQ, Buadi FK, Kapoor P, Hayman SR et al (2017) Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. Ann Med 49(7):545\u2013551. https:\/\/doi.org\/10.1080\/07853890.2017.1304649","journal-title":"Ann Med"},{"issue":"2","key":"7092_CR6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1080\/13506120802006187","volume":"15","author":"KS Naito","year":"2008","unstructured":"Naito KS, Ichiyama T, Kawakami S, Kadoya M, Tabata T, Matsuda M et al (2008) AL amyloidosis with spontaneous hepatic rupture: successful treatment by transcatheter hepatic artery embolization. Amyloid 15(2):137\u2013139. https:\/\/doi.org\/10.1080\/13506120802006187","journal-title":"Amyloid"},{"issue":"5","key":"7092_CR7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1097\/01.md.0000091183.93122.c7","volume":"82","author":"MA Park","year":"2003","unstructured":"Park MA, Mueller PS, Kyle RA, Larson DR, Plevak MF, Gertz MA (2003) Primary (AL) hepatic amyloidosis: clinical features and natural history in 98 patients. Med (Baltim) 82(5):291\u2013298. https:\/\/doi.org\/10.1097\/01.md.0000091183.93122.c7","journal-title":"Med (Baltim)"},{"issue":"11","key":"7092_CR8","doi-asserted-by":"publisher","first-page":"4695","DOI":"10.1007\/s12325-023-02637-4","volume":"40","author":"ML Mauermann","year":"2023","unstructured":"Mauermann ML, Clarke JO, Litchy WJ, Obici L, Lousada I, Gertz MA et al (2023) Peripheral nervous, hepatic, and gastrointestinal endpoints for AL amyloidosis clinical trials: report from the Amyloidosis Forum Multi-organ System Working Group. Adv Ther 40(11):4695\u20134710. https:\/\/doi.org\/10.1007\/s12325-023-02637-4","journal-title":"Adv Ther"},{"issue":"17","key":"7092_CR9","doi-asserted-by":"publisher","first-page":"8360","DOI":"10.1073\/pnas.1817567116","volume":"116","author":"GJ Morgan","year":"2019","unstructured":"Morgan GJ, Yan NL, Mortenson DE, Rennella E, Blundon JM, Gwin RM et al (2019) Stabilization of amyloidogenic immunoglobulin light chains by small molecules. Proc Natl Acad Sci U S A 116(17):8360\u20138369. https:\/\/doi.org\/10.1073\/pnas.1817567116","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"21","key":"7092_CR10","doi-asserted-by":"publisher","first-page":"4280","DOI":"10.1016\/j.jmb.2016.08.021","volume":"428","author":"GJ Morgan","year":"2016","unstructured":"Morgan GJ, Kelly JW (2016) The kinetic stability of a full-length antibody light chain dimer determines whether endoproteolysis can release amyloidogenic variable domains. J Mol Biol 428(21):4280\u20134297. https:\/\/doi.org\/10.1016\/j.jmb.2016.08.021","journal-title":"J Mol Biol"},{"issue":"15","key":"7092_CR11","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1182\/blood-2017-02-765560","volume":"129","author":"DE Reece","year":"2017","unstructured":"Reece DE (2017) Breaking bad...proteins. Blood 129(15):2041\u20132042. https:\/\/doi.org\/10.1182\/blood-2017-02-765560","journal-title":"Blood"},{"issue":"2","key":"7092_CR12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0889-8588(18)30347-2","volume":"6","author":"J Buxbaum","year":"1992","unstructured":"Buxbaum J (1992) Mechanisms of disease: monoclonal immunoglobulin deposition. Amyloidosis, light chain deposition disease, and light and heavy chain deposition disease. Hematol Oncol Clin North Am 6(2):323\u2013346","journal-title":"Hematol Oncol Clin North Am"},{"issue":"24","key":"7092_CR13","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMra2304088","volume":"390","author":"V Sanchorawala","year":"2024","unstructured":"Sanchorawala V (2024) Systemic light chain amyloidosis. N Engl J Med 390(24):2295\u20132307. https:\/\/doi.org\/10.1056\/NEJMra2304088","journal-title":"N Engl J Med"},{"issue":"1","key":"7092_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.17235\/reed.2022.8622\/2022","volume":"115","author":"E Dias","year":"2023","unstructured":"Dias E, Cardoso H, Marques M, Liberal R, Lopes S, Pereira P et al (2023) Hepatic amyloidosis: a prevalence study and clinical characterization of a rare and severe disease. Rev Esp Enferm Dig 115(1):16\u201321. https:\/\/doi.org\/10.17235\/reed.2022.8622\/2022","journal-title":"Rev Esp Enferm Dig"},{"key":"7092_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.humpath.2024.03.001","volume":"146","author":"S Yasir","year":"2024","unstructured":"Yasir S, Chen ZE, Hartley C, Zhang L, Torbenson M (2024) Morphological findings in different subtypes of hepatic amyloid. Hum Pathol 146:35\u201342. https:\/\/doi.org\/10.1016\/j.humpath.2024.03.001","journal-title":"Hum Pathol"},{"issue":"6","key":"7092_CR16","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/s0046-8177(88)80181-3","volume":"19","author":"LM Looi","year":"1988","unstructured":"Looi LM, Sumithran E (1988) Morphologic differences in the pattern of liver infiltration between systemic AL and AA amyloidosis. Hum Pathol 19(6):732\u2013735. https:\/\/doi.org\/10.1016\/s0046-8177(88)80181-3","journal-title":"Hum Pathol"},{"issue":"1","key":"7092_CR17","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1080\/07853890.2022.2069281","volume":"54","author":"L Zhao","year":"2022","unstructured":"Zhao L, Ren G, Guo J, Chen W, Xu W, Huang X (2022) The clinical features and outcomes of systemic light chain amyloidosis with hepatic involvement. Ann Med 54(1):1226\u20131232. https:\/\/doi.org\/10.1080\/07853890.2022.2069281","journal-title":"Ann Med"},{"key":"7092_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2019.106226","volume":"86","author":"LL Zhang","year":"2019","unstructured":"Zhang LL, Shen KN, Zhang CL, Qiu Y, Miao HL, Feng J et al (2019) Clinical presentation and prognostic analysis of Chinese patients with systemic light chain amyloidosis with liver involvement. Leuk Res 86:106226. https:\/\/doi.org\/10.1016\/j.leukres.2019.106226","journal-title":"Leuk Res"},{"issue":"1","key":"7092_CR19","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00277-024-05932-4","volume":"104","author":"AF Brunger","year":"2025","unstructured":"Brunger AF, Tingen HSA, Bijzet J, van Rheenen R, Blokzijl H, Roeloffzen WWH et al (2025) Diagnostic performance of liver stiffness as marker of liver involvement in systemic immunoglobulin light chain (AL) amyloidosis. Ann Hematol 104(1):653\u2013663. https:\/\/doi.org\/10.1007\/s00277-024-05932-4","journal-title":"Ann Hematol"},{"issue":"4","key":"7092_CR20","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1080\/13506129.2023.2222878","volume":"30","author":"AF Brunger","year":"2023","unstructured":"Brunger AF, van Rheenen R, Gans ROB, Hazenberg BPC, Nienhuis HLA (2023) How well does liver span as part of the consensus criteria for liver involvement in AL amyloidosis perform? Amyloid 30(4):437\u2013439. https:\/\/doi.org\/10.1080\/13506129.2023.2222878","journal-title":"Amyloid"},{"issue":"11","key":"7092_CR21","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.7863\/jum.2003.22.11.1155","volume":"22","author":"W Kratzer","year":"2003","unstructured":"Kratzer W, Fritz V, Mason RA, Haenle MM, Kaechele V, Roemerstein Study G (2003) Factors affecting liver size: a sonographic survey of 2080 subjects. J Ultrasound Med 22(11):1155\u20131161. https:\/\/doi.org\/10.7863\/jum.2003.22.11.1155","journal-title":"J Ultrasound Med"},{"issue":"1","key":"7092_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00789-8","volume":"13","author":"G Palladini","year":"2023","unstructured":"Palladini G, Schonland S, Merlini G, Milani P, Jaccard A, Bridoux F et al (2023) The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018. Blood Cancer J 13(1):19. https:\/\/doi.org\/10.1038\/s41408-023-00789-8","journal-title":"Blood Cancer J"},{"issue":"15","key":"7092_CR23","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1182\/blood-2016-11-751628","volume":"129","author":"E Muchtar","year":"2017","unstructured":"Muchtar E, Gertz MA, Kumar SK, Lacy MQ, Dingli D, Buadi FK et al (2017) Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death. Blood 129(15):2111\u20132119. https:\/\/doi.org\/10.1182\/blood-2016-11-751628","journal-title":"Blood"},{"issue":"9","key":"7092_CR24","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1002\/ajh.25149","volume":"93","author":"MA Gertz","year":"2018","unstructured":"Gertz MA (2018) Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment. Am J Hematol 93(9):1169\u20131180. https:\/\/doi.org\/10.1002\/ajh.25149","journal-title":"Am J Hematol"},{"issue":"1","key":"7092_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2227425","volume":"55","author":"M Chen","year":"2023","unstructured":"Chen M, Liu J, Wang X, Cao X, Gao X, Xu L et al (2023) Diagnosis for Chinese patients with light chain amyloidosis: a scoping review. Ann Med 55(1):2227425. https:\/\/doi.org\/10.1080\/07853890.2023.2227425","journal-title":"Ann Med"},{"issue":"7","key":"7092_CR26","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1182\/bloodadvances.2018016782","volume":"2","author":"MH Sidiqi","year":"2018","unstructured":"Sidiqi MH, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ et al (2018) Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation. Blood Adv 2(7):769\u2013776. https:\/\/doi.org\/10.1182\/bloodadvances.2018016782","journal-title":"Blood Adv"},{"issue":"6","key":"7092_CR27","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.hoc.2020.08.001","volume":"34","author":"G Bianchi","year":"2020","unstructured":"Bianchi G, Kumar S (2020) Systemic amyloidosis due to clonal plasma cell diseases. Hematol Oncol Clin North Am 34(6):1009\u20131026. https:\/\/doi.org\/10.1016\/j.hoc.2020.08.001","journal-title":"Hematol Oncol Clin North Am"},{"issue":"10","key":"7092_CR28","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1038\/s41375-018-0060-x","volume":"32","author":"E Muchtar","year":"2018","unstructured":"Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D et al (2018) Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia 32(10):2240\u20132249. https:\/\/doi.org\/10.1038\/s41375-018-0060-x","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"7092_CR29","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3109\/13506129.2011.574354033","volume":"18","author":"P Russo","year":"2011","unstructured":"Russo P, Palladini G, Foli A, Zenone Bragotti L, Milani P, Nuvolone M et al (2011) Liver involvement as the hallmark of aggressive disease in light chain amyloidosis: distinctive clinical features and role of light chain type in 225 patients. Amyloid 18(Suppl 1):92\u201393. https:\/\/doi.org\/10.3109\/13506129.2011.574354033","journal-title":"Amyloid"},{"issue":"5","key":"7092_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.34","volume":"5","author":"R Warsame","year":"2015","unstructured":"Warsame R, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR et al (2015) Abnormal FISH in patients with immunoglobulin light chain amyloidosis is a risk factor for cardiac involvement and for death. Blood Cancer J 5(5):e310. https:\/\/doi.org\/10.1038\/bcj.2015.34","journal-title":"Blood Cancer J"},{"issue":"4","key":"7092_CR31","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1080\/13506129.2020.1778461","volume":"27","author":"B Dumas","year":"2020","unstructured":"Dumas B, Yameen H, Sarosiek S, Sloan JM, Sanchorawala V (2020) Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen. Amyloid 27(4):244\u2013249. https:\/\/doi.org\/10.1080\/13506129.2020.1778461","journal-title":"Amyloid"},{"issue":"25","key":"7092_CR32","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1182\/blood.2024025899","volume":"144","author":"R Chakraborty","year":"2024","unstructured":"Chakraborty R, Zanwar S, Hegenbart U, Bhutani D, Gertz MA, Dispenzieri A et al (2024) Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy. Blood 144(25):2613\u20132624. https:\/\/doi.org\/10.1182\/blood.2024025899","journal-title":"Blood"},{"issue":"3","key":"7092_CR33","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1007\/s00277-025-06256-7","volume":"104","author":"S Oubari","year":"2025","unstructured":"Oubari S, Papathanasiou M, Michel L, Rassaf T, Thimm A, Hagenacker T et al (2025) Gain or amplification of 1q21 in systemic light chain amyloidosis is associated with advanced Mayo stage, plasma cell disease and worse overall survival. Ann Hematol 104(3):1777\u20131788. https:\/\/doi.org\/10.1007\/s00277-025-06256-7","journal-title":"Ann Hematol"},{"issue":"11","key":"7092_CR34","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.3324\/haematol.2025.287848","volume":"110","author":"MJ Rees","year":"2025","unstructured":"Rees MJ, Geyer S, Yohannan B, Toumeh N, Atallah-Yunes SA, Gertz MA et al (2025) Clonal plasma cell features in light chain amyloidosis are associated with depth and timing of cardiac response independent of hematologic response. Haematologica 110(11):2752\u20132763. https:\/\/doi.org\/10.3324\/haematol.2025.287848","journal-title":"Haematologica"},{"issue":"1","key":"7092_CR35","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/0002-9343(88)90505-0","volume":"85","author":"MA Gertz","year":"1988","unstructured":"Gertz MA, Kyle RA (1988) Hepatic amyloidosis (primary [AL], immunoglobulin light chain): the natural history in 80 patients. Am J Med 85(1):73\u201380. https:\/\/doi.org\/10.1016\/0002-9343(88)90505-0","journal-title":"Am J Med"},{"issue":"4","key":"7092_CR36","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1200\/JCO-25-02558","volume":"44","author":"J Khwaja","year":"2026","unstructured":"Khwaja J, Kirkwood AA, Milani P, Yohannan B, Theodorakakou F, Weverling F et al (2026) New validated staging system for light chain (AL) amyloidosis with stage IIIC defining ultra-poor risk: AL International Staging System. J Clin Oncol 44(4):311\u2013320. https:\/\/doi.org\/10.1200\/JCO-25-02558","journal-title":"J Clin Oncol"},{"key":"7092_CR37","doi-asserted-by":"publisher","first-page":"100509","DOI":"10.1016\/j.lrr.2025.100509","volume":"23","author":"M Ziarkiewicz","year":"2025","unstructured":"Ziarkiewicz M, Szczygiel J, Legatowicz-Koprowska M, Drozd-Sokolowska J, Boguradzki P, Jamroziak K et al (2025) AL amyloidosis with elevated peripheral blood cell counts - A frequent association with liver involvement. A single-center retrospective study. Leuk Res Rep 23:100509. https:\/\/doi.org\/10.1016\/j.lrr.2025.100509","journal-title":"Leuk Res Rep"},{"issue":"4","key":"7092_CR38","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.121.012506","volume":"14","author":"L Chacko","year":"2021","unstructured":"Chacko L, Boldrini M, Martone R, Law S, Martinez-Naharrro A, Hutt DF et al (2021) Cardiac magnetic resonance-derived extracellular volume mapping for the quantification of hepatic and splenic amyloid. Circ Cardiovasc Imaging 14(4):e012506. https:\/\/doi.org\/10.1161\/CIRCIMAGING.121.012506","journal-title":"Circ Cardiovasc Imaging"},{"issue":"36","key":"7092_CR39","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN et al (2012) New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 30(36):4541\u20134549. https:\/\/doi.org\/10.1200\/JCO.2011.37.7614","journal-title":"J Clin Oncol"},{"issue":"15","key":"7092_CR40","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","volume":"124","author":"G Palladini","year":"2014","unstructured":"Palladini G, Hegenbart U, Milani P, Kimmich C, Foli A, Ho AD et al (2014) A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood 124(15):2325\u20132332. https:\/\/doi.org\/10.1182\/blood-2014-04-570010","journal-title":"Blood"},{"issue":"3","key":"7092_CR41","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/ajh.23898","volume":"90","author":"GP Kaufman","year":"2015","unstructured":"Kaufman GP, Dispenzieri A, Gertz MA, Lacy MQ, Buadi FK, Hayman SR et al (2015) Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis. Am J Hematol 90(3):181\u2013186. https:\/\/doi.org\/10.1002\/ajh.23898","journal-title":"Am J Hematol"},{"key":"7092_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32080418","author":"E Lewis","year":"2025","unstructured":"Lewis E, Jimenez-Zepeda VH (2025) BCMA CAR-T: from multiple myeloma to light-chain amyloidosis. Curr Oncol. https:\/\/doi.org\/10.3390\/curroncol32080418","journal-title":"Curr Oncol"},{"key":"7092_CR43","unstructured":"Mayo Clinic (2026) Mayo Stratification for Myeloma and Risk-Adapted Therapy (mSMART). Treatment guidelines: multiple myeloma. Accessed 29 May 2026. https:\/\/www.msmart.org\/treatment-guidlines"},{"issue":"4","key":"7092_CR44","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1159\/000508262","volume":"143","author":"F Theodorakakou","year":"2020","unstructured":"Theodorakakou F, Fotiou D, Dimopoulos MA, Kastritis E (2020) Solid organ transplantation in amyloidosis. Acta Haematol 143(4):352\u2013364. https:\/\/doi.org\/10.1159\/000508262","journal-title":"Acta Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07092-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07092-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07092-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:42:41Z","timestamp":1789465361000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07092-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":44,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["7092"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07092-z","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"assertion":[{"value":"13 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of the Affiliated Taizhou People\u2019s Hospital of Nanjing Medical University Ethics Committee (No. KY2024-009-01). Written consent was obtained from the patient for publication of the case report and accompanying images.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"366"}}